News

DNAzyme controls skin cancer growth
Enlarge image

BusinessIreland

DNAzyme controls skin cancer growth

21.06.2012 - Researchers have halted the growth of skin cancer with help of a DNA that acts like an enzyme

Dublin/New South Wales – A DNA-based enzyme can block the growth of two common types of skin cancer, basal cell carcinoma and squamous cell carcinoma, an Australian-Irish team of researchers has demonstrated (Science Translational Medicine, 20 June). Dubbed Dz13, the DNAzyme could potentially be a safe and effective therapy for skin cancer in humans.

In animal models for both skin cancers as well as metastasis, the molecule stopped tumour spread and growth effectively by binding to and destroying the RNA of a key gene called c-Jun. The proliferation–related transcription factor controlled cancer growth by suppression of neovascularisation and increasing apoptosis of tumour cells. Phenotypically, the DNAzyme reduced lung nodule formation and an intratumour injection of 100 µg Dz13 led to complete tumour remission after 35 days.

Levon Khachigian and colleagues, who have filed an US patent on „vascular therapeutics“, also found that Dz13 probably triggers an immune response to inhibit tumour growth because it acts better in immunocompetent than in immunocompromised mice. In GLP-compliant toxicology tests, the researchers proved in monkeys, pigs and rats that Dz13 is safe and well tolerated. It did not interfere in more than 70 physiological relevant bioassays, suggesting a reduced propensity for off-target effects.

The authors suggest to test the compound in first-in-man trails. Up to now DNAzymes have not caught on as therapeutic agents partly due to the fact that delivery has been a challenge for DNAzyme therapeutic applications. Now, the researchers have formulated their c-jun mRNA–targeted DNAzyme in complex with a DOTAP/DOPE–based lipid carrier.

http://www.european-biotechnology-news.com/news/news/2012-02/dnazyme-controls-skin-cancer-growth.html

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Drug AssessmentPortugalFrance

18.01.2016 A Phase I clinical trial for a drug developed by Portuguese pharma company Bial has ended in disaster. One man died, five others may have irreversible neurological damage.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOCUTIS (UK)0.08 GBP14.29%
  • SERODUS (N)2.60 NOK4.00%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • DIAMYD MEDICAL -B- (S)4.30 SEK-12.24%

TOP

  • VERONA PHARMA (UK)3.35 GBP26.4%
  • IXICO (UK)34.00 GBP15.3%
  • WILEX (D)1.95 EUR14.7%

FLOP

  • BIONOR PHARMA (N)0.86 NOK-44.9%
  • PROTHENA PLC (IE)31.71 USD-41.1%
  • PLETHORA (UK)2.62 GBP-36.4%

TOP

  • KARO BIO (S)26.00 SEK3614.3%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • NICOX (F)7.00 EUR253.5%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.70 SEK-85.7%
  • BIOTEST (D)13.24 EUR-85.6%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 08.02.2016